- Home
- / Cannara Biotech
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Cannara Biotech financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$0.1
2021-05-12
Market Capitalization
$104.2 M
2021-05-12
Revenue
$107.3 M
FY, 2025
CreditSafe Score
?
Score changed on Jun 10, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| CAD | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2.6M | 16.3M | 36.0M | 57.6M | 82.1M | 107.3M | ||
| Cost of goods sold | 913.0K | 8.5M | 19.0M | 32.5M | 49.0M | 57.3M | ||
| Gross profit | 2.1M | 1.7M | 8.8M | 17.0M | 25.1M | 33.2M | 50.0M | |
| Gross profit margin, % | 53.8% | 47.2% | 43.5% | 40.4% | 46.6% | |||
| Operating expense total | 75.0K | 11.9M | 10.2M | 8.0M | 10.4M | 13.7M | 21.1M | 24.3M |
| Depreciation and amortization | 425.0K | 1.6M | 1.0M | 4.1M | 4.9M | 6.4M | 6.7M | |
| EBITDA | (75.0K) | (9.8M) | (8.5M) | 745.0K | 6.6M | 11.4M | 12.1M | 25.8M |
| EBITDA margin, % | 4.6% | 18.4% | 19.8% | 14.7% | 24.0% | |||
| EBIT | (75.0K) | (12.1M) | (10.6M) | 1.4M | 5.8M | 12.8M | 10.1M | 22.2M |
| EBIT margin, % | 8.9% | 16.2% | 22.3% | 12.3% | 20.7% | |||
| Interest income | 266.0K | 53.0K | 93.0K | 239.0K | 190.0K | 281.0K | ||
| Interest expense | 873.0K | 1.4M | 1.7M | 3.3M | 5.3M | 5.7M | 4.4M | |
| Pre tax profit | (75.0K) | (13.0M) | (13.1M) | (1.5M) | 2.3M | 6.9M | 4.5M | 18.1M |
| Income tax expense | (2.0M) | 5.0M | ||||||
| Net Income | (75.0K) | (13.0M) | (13.1M) | (1.5M) | 2.3M | 6.9M | 6.4M | 13.1M |